ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • geographic disparity and mortality rates
  • geriatrics
  • Geriatrics and glomerulonephritis
  • geriatrics and gout
  • geriatrics and hydroxychloroquine
  • geriatrics and longitudinal studies
  • geriatrics and patient-reported outcome measures
  • geriatrics and rheumatoid arthritis (RA)
  • GGT
  • GI
  • giant cell arteritis
  • giant cell arteritis and cytokines
  • giant cell arteritis and diagnostic imaging
  • giant cell arteritis and Doppler ultrasound
  • giant cell arteritis and evolution
  • giant cell arteritis and fibroblasts
  • giant cell arteritis and glucocorticoids
  • giant cell arteritis and glycoproteins
  • giant cell arteritis and heart disease
  • giant cell arteritis and histopathologic
  • giant cell arteritis and human leukocyte antigens (HLA)
  • Giant cell arteritis and imaging techniques
  • Giant cell arteritis and infection
  • giant cell arteritis and inflammation
  • Giant cell arteritis and interleukins (IL)
  • giant cell arteritis and large vessel vasculitis
  • Giant cell arteritis and malignancy
  • Giant cell arteritis and management
  • giant cell arteritis and meta-analysis
  • Giant cell arteritis and metabolic syndrome
  • giant cell arteritis and metabolism
  • giant cell arteritis and methotrexate (MTX)
  • giant cell arteritis and microbiome
  • giant cell arteritis and morbidity and mortality
  • Giant cell arteritis and patient outcomes
  • giant cell arteritis and patient-reported outcome measures
  • giant cell arteritis and pharmacology
  • giant cell arteritis and physical activity
  • giant cell arteritis and physical function
  • giant cell arteritis and PK
  • giant cell arteritis and polymorphism
  • giant cell arteritis and polymyalgia rheumatica
  • giant cell arteritis and population studies
  • giant cell arteritis and positron emission tomography (PET)
  • Giant cell arteritis and prednisolone
  • giant cell arteritis and prevention
  • giant cell arteritis and quality improvement
  • giant cell arteritis and socio-economic inequities
  • giant cell arteritis and statins
  • giant cell arteritis and steroids
  • giant cell arteritis and takayasu arteritis
  • giant cell arteritis and temporal arteritis
  • Giant cell arteritis and therapy
  • Giant cell arteritis and thrombosis
  • Giant cell arteritis and thyroid
  • giant cell arteritis and tocilizumab
  • Giant cell arteritis and ultrasonography
  • giant cell arteritis and ultrasound
  • giant cell arteritis and vasculitis
  • giant cell arteritis and vessel vasculitis
  • GILZ
  • glomerulonephritis
  • glomerulonephritis and Elderly
  • glomerulonephritis and histopathologic
  • glomerulonephritis and imaging techniques
  • glomerulonephritis and inflammation
  • glomerulonephritis and interferons
  • glomerulonephritis and lupus nephritis
  • glomerulonephritis and macrophages
  • glomerulonephritis and nephritis
  • glomerulonephritis and renal disease
  • glomerulonephritis and skin
  • glomerulonephritis and systemic lupus erythematosus (SLE)
  • glomerulonephritis and toll-like receptors
  • Glomerulonephritis and transcription factor
  • glomerulonephritis and transplantation
  • glomerulonephritis and vasculitis
  • glomerulonephritis and viruses
  • glucocorticoids
  • glucocorticoids and 25-hydroxyvitamin D
  • glucocorticoids and Biologics
  • glucocorticoids and bisphosphonates
  • glucocorticoids and cardiovascular disease
  • glucocorticoids and Cell Migration
  • glucocorticoids and computed tomography (CT)
  • glucocorticoids and Disease Activity
  • glucocorticoids and health care cost
  • glucocorticoids and inflammatory arthritis
  • glucocorticoids and innate immunity
  • glucocorticoids and lupus nephritis
  • glucocorticoids and macrophages
  • glucocorticoids and meta-analysis
  • glucocorticoids and mitochondria
  • glucocorticoids and nutrition
  • glucocorticoids and obesity
  • glucocorticoids and osteoarthritis
  • glucocorticoids and osteoblasts
  • glucocorticoids and osteonecrosis
  • glucocorticoids and osteoporosis
  • glucocorticoids and outcome measures
  • glucocorticoids and outcomes
  • glucocorticoids and parathyroid hormone
  • glucocorticoids and pediatric rheumatology
  • glucocorticoids and pharmacokinetics
  • Glucocorticoids and polymyalgia rheumatica
  • glucocorticoids and population studies
  • glucocorticoids and pregnancy
  • glucocorticoids and quality improvement
  • glucocorticoids and remission
  • glucocorticoids and rheumatic disease
  • glucocorticoids and rheumatoid arthritis
  • glucocorticoids and rheumatoid arthritis (RA)
  • glucocorticoids and Rheumatology
  • glucocorticoids and risk assessment
  • glucocorticoids and rituximab
  • glucocorticoids and synovial cells
  • Glucocorticoids and systemic lupus erythematosus (SLE)
  • glucocorticoids and systemic vasculitides
  • glucocorticoids and tocilizumab
  • glucocorticoids and trainee
  • glucocorticoids and treatment
  • glucocorticoids and treatment options
  • glucocorticoids and vasculitis
  • Glucosamine
  • glucosamine and low back pain
  • glucosamine and osteoarthritis
  • glutamate
  • gluten sensitivity
  • glycoproteins
  • glycoproteins and juvenile idiopathic arthritis (JIA)
  • glycoproteins and lipids
  • glycoproteins and myositis
  • glycoproteins and osteoarthritis
  • Glycoproteins and psoriatic arthritis
  • glycoproteins and rheumatoid arthritis
  • glycoproteins and rheumatoid arthritis (RA)
  • glycostransferases
  • glycostransferases and rheumatoid arthritis (RA)
  • GO-VIBRANT
  • goals and objectives
  • goals of care
  • GOBP
  • Golimumab
  • gout
  • gout and allopurinol
  • gout and arthrocentesis
  • gout and cardiovascular disease
  • gout and crystals
  • gout and Gene Expression
  • gout and health care cost
  • gout and heart disease
  • gout and heart failure
  • gout and histone acetylation
  • gout and hyperuricemia
  • gout and imaging techniques
  • Gout and inflammasome activation
  • Gout and inflammation
  • gout and inflammatory arthritis
  • gout and innate immunity
  • Gout and interleukins (IL)
  • gout and internet
  • gout and knowledge
  • gout and laboratory tests
  • Gout and magnetic resonance imaging (MRI)
  • gout and malignancy
  • Gout and management
  • gout and medical management
  • gout and medication
  • Gout and meta-analysis
  • Gout and metabolic syndrome
  • gout and metabolism
  • Gout and methotrexate (MTX)
  • gout and mitochondria
  • gout and morbidity and mortality
  • gout and muscle strength
  • gout and musculoskeletal sonography
  • gout and myocardial involvement
  • Gout and nanomedicine
  • gout and neutrophils
  • gout and nonsteroidal antiinflammatory drugs (NSAIDs)
  • Gout and nutrition
  • gout and obesity
  • gout and online resources
  • Gout and opioids
  • gout and osteoarthritis
  • gout and osteoprotegerin
  • Gout and outcome measures
  • gout and outcomes
  • gout and pain
  • Gout and pathogenesis
  • Gout and patient outcomes
  • gout and pharmacotherapy
  • gout and physical function
  • gout and population studies
  • gout and prescribing trends
  • gout and Prevalence
  • gout and prevention
  • gout and primary care
  • Gout and pseudogout
  • Gout and quality
  • First |
  • « Previous Page
  • 20
  • 21
  • 22
  • 23
  • 24
  • [25]
  • 26
  • 27
  • 28
  • 29
  • 30
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology